On September 27, 2021 Amplia Therapeutics Limited (ASX: ATX) ("Amplia" or the "Company") reported that it will be providing a presentation at the Proactive Investors Lifesciences Webinar at 12:00 pm AEST on Tuesday 28 September 2021 (Press release, Amplia Therapeutics, SEP 27, 2021, View Source;[email protected] [SID1234590271]). The webinar will include results from the Company’s successful Phase 1 clinical trial of AMP945 and its plans for a Phase 2 clinical trial in first-line pancreatic cancer that is scheduled to commence in early 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To join the webinar, please register at: View Source

This ASX announcement was approved and authorised for release by the CEO of Amplia Therapeutics.